2025-10-01 - Analysis Report
Okay, here's an analysis of TransMedics Group Inc. (TMDX) based on the data provided, formatted as requested.

## TMDX (TransMedics Group Inc.) Analysis

**Company Overview:** TransMedics Group Inc. is a medical technology company focused on preserving and assessing organs for transplantation.

### 1. Performance vs. S&P 500 (VOO)

*   **TMDX Cumulative Return:** 184.66%
*   **VOO Cumulative Return:** 72.81%
*   **Absolute Divergence (Current):** 123.0
*   **Relative Divergence:** 63.8 (Indicates current divergence is in the higher range of historical divergence)

**Analysis:** TMDX has significantly outperformed the S&P 500. The relative divergence suggests that while the outperformance is substantial, it's not at its historical peak relative to the benchmark.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha  | Beta | Cap(B) |
|------------|---------|-------|--------|------|--------|
| 2019-2021  | -18.0%  | 83.5% | -61.0% | -0.0 | 0.7    |
| 2020-2022  | 94.0%   | 83.5% | 95.0%  | 0.0  | 2.1    |
| 2021-2023  | 65.0%   | 80.5% | 64.0%  | 0.1  | 2.7    |
| 2022-2024  | 130.0%  | 85.5% | 109.0% | 0.1  | 2.1    |
| 2023-2025  | 105.0%  | 85.5% | 43.0%  | 0.3  | 3.9    |

**Analysis:**

*   **CAGR:**  Shows substantial growth in recent periods (2020-2025), indicating strong performance.
*   **MDD:** High Maximum Drawdown values suggest significant volatility.
*   **Alpha:**  Consistently positive Alpha values indicate TMDX has been generating excess returns relative to its risk (beta).
*   **Beta:**  Low Beta values suggest TMDX's price is not highly correlated with the overall market.  The increasing Beta over time (particularly in the most recent period) *could* indicate a slightly increased sensitivity to market movements, but it's still relatively low.

### 2. Recent Price Action

*   **Current Price:** 112.69
*   **Last Market Data:** price: 112.5075, previousClose: 112.64, change: -0.12 (slight decrease)
*   **5-day Moving Average:** 114.96
*   **20-day Moving Average:** 113.68
*   **60-day Moving Average:** 116.44

**Analysis:** The current price is below the 5-day, 20-day, and 60-day moving averages, suggesting a short-term downward trend. The price change of -0.12 indicates a minor negative movement in the last market session.

### 3. Technical Indicators and Outlook

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 56.0 (Neutral)
*   **PPO:** -0.08 (Bearish signal, but close to zero)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90)
*   **Recent (20-day) Relative Divergence Change:** -6.7 (Indicates a short-term decrease in relative outperformance)
*   **Expected Return:** 40.8% (Projected excess return over S&P 500 with long-term accumulation)

**Analysis:** The MRI suggests a favorable investment environment. RSI is neutral, not indicating overbought or oversold conditions. The negative PPO might indicate a slight bearish momentum. The recent decrease in relative divergence aligns with the price action, suggesting recent underperformance relative to VOO. The high expected return suggests strong long-term potential.

### 4. Recent News & Events

*   **Positive Coverage:** Several articles highlight TMDX's growth potential and potential undervaluation.
*   **Strategic Partnership:** The collaboration with Mercedes-Benz for organ transport in Italy is a significant positive development.

**Analysis:** The recent news is predominantly positive, pointing to potential growth drivers and strategic initiatives. The Mercedes-Benz partnership especially suggests innovation and market expansion.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (~1.82)
*   **Target Price (Avg/High/Low):** 140.67 / 170.00 / 114.00

**Analysis:** Analyst consensus is strongly bullish. The average target price of $140.67 represents a significant upside from the current price, while the low target price still represents a small upside.

### 5. Recent Earnings Analysis

| Date       | EPS   | Expected EPS |
|------------|-------|--------------|
| 2025-07-30 | 0.92  | 0.48         |
| 2025-05-08 | 0.70  | 0.29         |
| 2025-02-27 | 0.19  | 0.22         |
| 2024-10-28 | 0.12  | 0.29         |
| 2024-07-31 | 0.35  | 0.21         |

**Analysis:** TMDX has consistently exceeded EPS expectations in recent quarters, indicating strong earnings performance. The large beats in the most recent quarters (2025-07-30 and 2025-05-08) are particularly noteworthy.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | $0.16B   | 61.38%        |
| 2025-03-31 | $0.14B   | 61.47%        |
| 2024-12-31 | $0.12B   | 59.21%        |
| 2024-09-30 | $0.11B   | 55.94%        |
| 2024-06-30 | $0.11B   | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE       |
|------------|----------|-----------|
| 2025-06-30 | $0.32B   | 10.97%    |
| 2025-03-31 | $0.27B   | 9.64%     |
| 2024-12-31 | $0.23B   | 3.00%     |
| 2024-09-30 | $0.21B   | 2.01%     |
| 2024-06-30 | $0.19B   | 6.42%     |

**Analysis:** Revenue has been steadily increasing. The profit margins are consistently high, indicating strong profitability. Equity is growing, and ROE has improved significantly, reflecting better utilization of equity to generate profits.

### 7. 종합 Summary

TMDX exhibits strong growth potential. It has significantly outperformed the S&P 500, with high revenue growth and high profit margins. Recent earnings beats and positive analyst ratings reinforce the bullish outlook. The partnership with Mercedes-Benz suggests innovation and market expansion. While there are some short-term bearish signals in the price action and PPO, the overall picture points to a promising investment opportunity for long-term investors. The High Investment Recommended MRI suggests a favorable environment for investment at this time.

